Gene
FOLR1
FOLR1 is a gene biomarker in the evidence tier "FDA companion diagnostic". This page lists evidence by type: FDA companion diagnostic assertions (1), Assay-provider ledger (34), Trial mentions (63), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
FDA companion diagnostic
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention FOLR1. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 10 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 12 of 8,738 | 0.14% | not measured | |
| 2025 | 10 of 8,875 | 0.11% | not measured | |
| 2024 | 8 of 8,597 | 0.09% | not measured | |
| 2023 | 7 of 8,275 | 0.08% | 12 of 11,460 | 0.10% |
| 2022 | 4 of 8,285 | 0.05% | 5 of 13,598 | 0.04% |
| 2021 | 3 of 8,692 | 0.03% | 9 of 15,045 | 0.06% |
| 2020 | 2 of 7,640 | 0.03% | 8 of 14,459 | 0.06% |
| 2019 | 4 of 7,300 | 0.05% | 5 of 12,159 | 0.04% |
| 2018 | 1 of 6,927 | 0.01% | 6 of 11,854 | 0.05% |
| 2017 | 3 of 6,558 | 0.05% | 5 of 11,595 | 0.04% |
Showing 10 of 37 years.
FDA companion diagnostic assertions (1)
Shown in this order: most recent decision first.
| Diagnostic | Source biomarker wording | Manufacturer | Indication | Decision date |
|---|---|---|---|---|
| Ventana FOLR1 (FOLR-2.1) RxDx Assay | FOLR1 | Ventana Medical Systems, Inc. | Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | 2022-11-14 |
Assay-provider ledger (34)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| GenoSaber Biotech | Diagnostic provider | Clinical validation | 2 | June 28, 2026 |
| ImmunoGen | Pharma or other | Clinical validation | 1 | January 01, 2026 |
| CytoLumina Technologies Corp. | Diagnostic provider | Clinical validation | 1 | September 01, 2025 |
| Eximius Diagnostics Corp | Diagnostic provider | Clinical validation | 1 | September 01, 2025 |
| Pulsar Therapeutics | Pharma or other | Clinical validation | 1 | September 01, 2025 |
Showing 5 of 34 assay-provider companies.
Trial mentions (63)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT07690332 | Trial biospecimen (AACT) |
| NCT06609928 | Trial eligibility (AACT) |
| NCT07617753 | Trial eligibility (AACT) |
| NCT05870748 | Trial eligibility (AACT) |
| NCT03854110 | Trial eligibility (AACT) |
Showing 5 of 63 trial mentions.
Target-disease associations (109)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| Alzheimer disease | nervous system disease | Literature (Europe PMC) |
| Autosomal dominant polycystic kidney disease | genetic, familial or congenital disease | Literature (Europe PMC) |
| Barrett's esophagus | gastrointestinal disease | Expression Atlas |
| Epileptic encephalopathy | phenotype | Variant curation (ClinVar / EVA) |
| Mobius syndrome | disorder of visual system | Literature (Europe PMC) |
Showing 5 of 109 associations.
Vendor sourcing (207)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The variant is not observed in the gnomAD v2.1.1 dataset. Predicted Consequence/Location: Stop-gained (nonsense) - predicted to result in a loss or disruptio... | View ClinVar record SCV005905004.1 |
| AGO Research GmbH | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : 1. All patients must have a pathologically documented, definite diagnosis of epithelial cancer of the ovary, the fallopian tube or the peritoneum 2. Relap... | View trial NCT04274426 |
| AGO Research GmbH | Trial sponsor | Mentioned in trial textTrial free-text mention | FOLR1 | View trial NCT04274426 |
| ARUP Laboratories (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | No supporting text recorded; see the citation. | View ClinVar record SCV005878107.1 |
| AbbVie Inc. | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : * Provision to sign and date the consent form * Stated willingness to comply with all study procedures and be available for the duration of the study * Be... | View trial NCT05887609 |
Showing 5 of 207 sourcing records.
Trial-cited literature (111)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| The efficacy and safety of mirvetuximab soravtansine in FRα-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II PICCOLO trial. | Annals of oncology : official journal of the European Society for Medical Oncology | 2025 | 43 |
| Cancer of the ovary, fallopian tube, and peritoneum: 2025 update. | International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics | 2025 | 27 |
| Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial. | The Lancet. Oncology | 2025 | 27 |
| Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancer. | Gynecologic oncology | 2025 | 14 |
| Non-Allergic Urticarial Skin Reactions Associated With MOv18 IgE, a First-In-Class IgE Antibody Recognising Folate Receptor Alpha. | Allergy | 2025 | 4 |
Showing 5 of 111 papers.
Protein variant mentions (10)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A226V | 1 | 2010 | PMID 20841559 |
| p.A64S | 1 | 2015 | PMID 25741868 |
| p.N35D | 1 | 2015 | PMID 25741868 |
| p.Q118* | 1 | 2015 | PMID 25741868 |
| p.R204* | 1 | 2015 | PMID 25741868 |
Showing 5 of 10 variants.
Literature-extracted relations (37)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Platinum | Chemical | associate |
Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial. | 2025 |
| Folic (or folinic) acid | Chemical | negative_correlate |
Low-dose daily folic acid (400 μg) supplementation does not affect regulation of folate transporters found present throughout the terminal ileum and colon of humans: a randomized clinical trial. | 2024 |
| Folic (or folinic) acid | Chemical | associate |
Treatment of Folate Metabolism Abnormalities in Autism Spectrum Disorder. | 2020 |
| Folic (or folinic) acid | Chemical | associate |
Membrane folate-binding proteins are responsible for folate-protein conjugate endocytosis into cultured cells. | 1993 |
| Ovarian Neoplasms | Disease | associate |
Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial. | 2025 |
Showing 5 of 37 relation assertions.
Organizations publishing (130)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | Hospital | 6 | 2015 to 2024 |
| Dana-Farber Cancer Institute | Other | 5 | 2017 to 2025 |
| Harvard Medical School | Academic | 5 | 2016 to 2021 |
| University of California System | Academic | 5 | 2011 to 2021 |
| CERCA Institution | Government | 4 | 2021 to 2025 |
Showing 5 of 130 organizations.
Where FOLR1 appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- immune system disease
- infectious disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- reproductive system or breast disease
92 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda biomarker qualification projects, actionable biomarkers, and human sample screening reference.